Cervical Cancer Clinical Trials (as of February 2024)

 

ENGOT-cx19/GEICO/eVOLVE

Leading group: GINECO

Clinical Trial Study: PARa-aOrtic LymphAdenectomy in LACC

Planned number of patients: 520

Participating groups: Swiss GO, BGOG, GEICO, NCRI UK

 

ENGOT-cx18/GINECO/PAROLA

Leading group: GINECO

Clinical Trial Study: PARa-aOrtic LymphAdenectomy in LACC

Planned number of patients: 520

Participating groups: Swiss GO, BGOG, GEICO, NCRI UK

 

ENGOT-cx17/GINECO/BRAVA

Leading group: GINECO

Clinical Trial Study: Anti-PD-L1 Balstilimab vs Investigator Choice Chemotherapy in Patients with Recurrent Cervical Cancer  

Planned number of patients: 486

Participating groups: A-AGO,AGO, GEICO, MITO, CEEGOG, SAKK, PGOG, CTI, BGOG, TRSGO, HeCOG, NSGO-CTU, MaNGO, NOGGO, ISGO

 

ENGOT-cx16/CEEGOG/CERVANTES

Leading group: CEEGOG

Clinical Trial Study: CERVANTES (CERVical cancer AdjuvaNt Treatment Study)​ - ​An international randomized trial of radical surgery followed by adjuvant  (chemo)radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer patients​

Planned number of patients: 514

Participating groups: PGOG, BGOG, AGO

 

ENGOT-cx15/GEICO/102C

Leading group: GEICO

Clinical Trial Study: GOG-3056 EMD Serono 1L Cervical Ph3 chemo/combo  

Planned number of patients: TBA

Participating groups:  AGO, GINECO, MITO

 

ENGOT-cx13/AGO/FERMATA

Leading group: AGO

Clinical Trial Study: FERMATA Trial: An international randomized double-blind clinical trial of BCD-100 plus platinum-based chemotherapy with and without Bevacizumab versus placebo plus platinum-based chemotherapy with and without Bevacizumab as first-line treatment of subjects with advanced cervical cancer

Planned number of patients: 316

Participating groups:  A-AGO, BGOG, CEEGOG, NSGO, PGOG

 

ENGOT-cx12/BGOG-cx12

Leading group: BGOG

Clinical Trial Study: Phase 3, randomized controlled trial of Tisotumab Vedotin vs Investigator’s choice chemotherapy in 2nd or 3rd line recurrent cervical cancer

Planned number of patients: 482

Participating groups:  NSGO, AGO, MITO, GEICO, GINECO, A-AGO, CEEGOG, CTI, NCRI, DGOG, MaNGO, PGOG

 

ENGOT-cx11/MITO/LACC

Leading group: MITO

Clinical Trial Study: A randomized, phase 3, double-blind study of chemoradiotherapy with or without pembrolizumab for the treatment of high-risk, locally advanced cervical cancer

Planned number of patients: 980

Participating groups: MaNGO, BGOG, CTI, GINECO, HeCOG, CEEGOG, GEICO, ISGO, NCRI, NOGGO, NSGO, A-AGO, MITO, TRSGO, GOG

 

ENGOT-cx4/GINECO/SENTICOL

Leading group: GINECO

Clinical Trial Study: International prospective validation trial of sentinel node biopsy in cervical cancer

Planned number of patients: 950

Participating groups: AGO, MaNGO, NSGO, DGOG, CEEGOG, GCIG, Gotic, KoIGO Trg, CHRU